The Koch Institute High Throughput Sciences Core (HTS Core) provides automated technologies, expertise and training that allows Cancer Center Members to investigate the interplay between biomaterials, biomolecules, small molecules and cells in a high-throughput, multiplexed manner to enable drug and gene discovery, drug delivery, toxicology, and systems biology applications. The HTS Core possesses state-of-the-art robotic instrumentation, an array of biological tools, including validated cell lines and curated libraries, and an exceptional staff with expertise in assay development and adaptation, screening execution, and robotics workflows. HTS Core activities were established in 2011, with support from CCSG Developmental Funds and Institutional support. In the prior submission, HTS activities were embedded in the Koch Institute Genomics Core, reflecting their extensive interactions. During this current period, the HTS Core has greatly expanded its roles and impact for both Center Members and other Koch Institute Cores. Given this, and on the advice of our SAB, we are requesting funding for High Throughput Sciences as a stand-alone Core. In the current funding period, the HTS Core added a significant number of new capabilities and modified existing services, including: a new high throughput flow cytometer and tissue processing equipment; added >55,000 new compounds to small molecule libraries; automated workflows for ELISAs, high content imaging and HT sample preparation pipelines, including automated plate-based HT ChIP-Seq sample preparation (collaborating with the Integrated Genomics & Bioinformatics Core); and cell line management services, including mycoplasma testing and banking of mycoplasma-free cell lines. Center Member Core use has been strong: 66% of Center Members use the Core, account for 73% of Core service use, and include investigators from all three Research Programs. In the upcoming period, the HTS Core will continue to offer a wide range of state-of-the-art services to support Center Member research programs, and will evaluate emerging capabilities in the context of Center Member needs and interests. A number of new initiatives are planned, including: acquisition and evaluation of new equipment; upgrades to existing equipment; acquisition of new CRISPR and targeted small molecule libraries; establishment of small molecule screening in zebrafish; continued collaboration with other Koch Institute Core Facilities to develop technology and streamline workflows; deployment of a custom-built LIMS system to manage library materials and screening assay data; dataset sharing to support development of machine learning algorithms; and collaborating with other Koch Institute Cores to develop a monthly workshop series to support Center Members? access to imaging technology platforms and data analysis. This Shared Resource is essential to the success of the Koch Institute mission and provides exceptional value to the CCSG. The requested CCSG budget for Year 49 is increased by 1.6% over the Core CCSG budget for the current period (Year 48).

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA014051-49
Application #
9937092
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2020-05-01
Budget End
2021-04-30
Support Year
49
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Massachusetts Institute of Technology
Department
Type
DUNS #
001425594
City
Cambridge
State
MA
Country
United States
Zip Code
02142
Weidberg, Hilla; Amon, Angelika (2018) MitoCPR-A surveillance pathway that protects mitochondria in response to protein import stress. Science 360:
Chiu, Anthony C; Suzuki, Hiroshi I; Wu, Xuebing et al. (2018) Transcriptional Pause Sites Delineate Stable Nucleosome-Associated Premature Polyadenylation Suppressed by U1 snRNP. Mol Cell 69:648-663.e7
Nagarajan, Maxwell B; Tentori, Augusto M; Zhang, Wen Cai et al. (2018) Nonfouling, Encoded Hydrogel Microparticles for Multiplex MicroRNA Profiling Directly from Formalin-Fixed, Paraffin-Embedded Tissue. Anal Chem 90:10279-10285
Mead, Benjamin E; Ordovas-Montanes, Jose; Braun, Alexandra P et al. (2018) Harnessing single-cell genomics to improve the physiological fidelity of organoid-derived cell types. BMC Biol 16:62
Chen, Tiffany F; Li, Kevin K; Zhu, Eric F et al. (2018) Artificial Anti-Tumor Opsonizing Proteins with Fibronectin Scaffolds Engineered for Specificity to Each of the Murine Fc?R Types. J Mol Biol 430:1786-1798
Dayton, Talya L; Gocheva, Vasilena; Miller, Kathryn M et al. (2018) Isoform-specific deletion of PKM2 constrains tumor initiation in a mouse model of soft tissue sarcoma. Cancer Metab 6:6
Koblan, Luke W; Doman, Jordan L; Wilson, Christopher et al. (2018) Improving cytidine and adenine base editors by expression optimization and ancestral reconstruction. Nat Biotechnol 36:843-846
Suarez-Lopez, Lucia; Sriram, Ganapathy; Kong, Yi Wen et al. (2018) MK2 contributes to tumor progression by promoting M2 macrophage polarization and tumor angiogenesis. Proc Natl Acad Sci U S A 115:E4236-E4244
Guner-Ataman, Burcu; González-Rosa, Juan Manuel; Shah, Harsh N et al. (2018) Failed Progenitor Specification Underlies the Cardiopharyngeal Phenotypes in a Zebrafish Model of 22q11.2 Deletion Syndrome. Cell Rep 24:1342-1354.e5
Phizicky, David V; Berchowitz, Luke E; Bell, Stephen P (2018) Multiple kinases inhibit origin licensing and helicase activation to ensure reductive cell division during meiosis. Elife 7:

Showing the most recent 10 out of 904 publications